Role of IGF-I on PTH effects on bone.

G. Lombardi, C. Di Somma, L. Vuolo, E. Guerra, E. Scarano, A. Colao

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

IGF-I and PTH have synergistic actions on bone and some effects of the anabolic actions of PTH are mediated by local production of IGF-I, as has been shown in vitro and in vivo studies both in animals and humans. PTH can induce skeletal IGF-I expression both in vitro and in vivo. In chondrocytes, IGF-I synthesis is under GH control, whereas in osteoblasts its synthesis is fundamentally under the control of PTH. PTH stimulates the synthesis of IGF-I via a cAMP-dependent mechanism, and this factor has pro-differentiating and prosurvival effects on osteoblasts. In in vitro studies, IGF-I and PTH have shown a synergistic action on the osteoblasts of bone marrow. Human clinical data confirm the interactions between PTH and GH-IGF-I axis on bone. PTH is involved in the development of osteoporosis in adult patients with GH deficiency (GHD). In fact, patients with GHD show renal, skeletal, and intestinal cell insensitivity to PTH, leading to a mild state of PTH resistance and increased serum PTH levels. In addition, GH replacement in these patients restores PTH secretory rhythm, increases bone turnover markers, 1,25-dihydroxy vitamin D concentration, and Ca absorption/reabsorption, thus contributing to the positive effects of GH on bone. On the other hand, in post-menopausal women with primary hyperparathyroidism a reduced secretion of GH is observed, in association with a greater impairment of bone mass. GH administration resulted in increased IGF-I concentration, decreased PTH concentration, and increased nephrogenous cAMP. In conclusion, the anabolic action of PTH requires paracrine and autocrine effects of IGF-I.

Original languageEnglish
Pages (from-to)22-26
Number of pages5
JournalJournal of Endocrinological Investigation
Volume33
Issue number7 Suppl
Publication statusPublished - 2010

Fingerprint

Insulin-Like Growth Factor I
Bone and Bones
Osteoblasts
Primary Hyperparathyroidism
Bone Remodeling
Chondrocytes
Vitamin D
Osteoporosis
Bone Marrow
Kidney
Serum

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Lombardi, G., Di Somma, C., Vuolo, L., Guerra, E., Scarano, E., & Colao, A. (2010). Role of IGF-I on PTH effects on bone. Journal of Endocrinological Investigation, 33(7 Suppl), 22-26.

Role of IGF-I on PTH effects on bone. / Lombardi, G.; Di Somma, C.; Vuolo, L.; Guerra, E.; Scarano, E.; Colao, A.

In: Journal of Endocrinological Investigation, Vol. 33, No. 7 Suppl, 2010, p. 22-26.

Research output: Contribution to journalArticle

Lombardi, G, Di Somma, C, Vuolo, L, Guerra, E, Scarano, E & Colao, A 2010, 'Role of IGF-I on PTH effects on bone.', Journal of Endocrinological Investigation, vol. 33, no. 7 Suppl, pp. 22-26.
Lombardi G, Di Somma C, Vuolo L, Guerra E, Scarano E, Colao A. Role of IGF-I on PTH effects on bone. Journal of Endocrinological Investigation. 2010;33(7 Suppl):22-26.
Lombardi, G. ; Di Somma, C. ; Vuolo, L. ; Guerra, E. ; Scarano, E. ; Colao, A. / Role of IGF-I on PTH effects on bone. In: Journal of Endocrinological Investigation. 2010 ; Vol. 33, No. 7 Suppl. pp. 22-26.
@article{12c14ffa05224832901602030f876a7c,
title = "Role of IGF-I on PTH effects on bone.",
abstract = "IGF-I and PTH have synergistic actions on bone and some effects of the anabolic actions of PTH are mediated by local production of IGF-I, as has been shown in vitro and in vivo studies both in animals and humans. PTH can induce skeletal IGF-I expression both in vitro and in vivo. In chondrocytes, IGF-I synthesis is under GH control, whereas in osteoblasts its synthesis is fundamentally under the control of PTH. PTH stimulates the synthesis of IGF-I via a cAMP-dependent mechanism, and this factor has pro-differentiating and prosurvival effects on osteoblasts. In in vitro studies, IGF-I and PTH have shown a synergistic action on the osteoblasts of bone marrow. Human clinical data confirm the interactions between PTH and GH-IGF-I axis on bone. PTH is involved in the development of osteoporosis in adult patients with GH deficiency (GHD). In fact, patients with GHD show renal, skeletal, and intestinal cell insensitivity to PTH, leading to a mild state of PTH resistance and increased serum PTH levels. In addition, GH replacement in these patients restores PTH secretory rhythm, increases bone turnover markers, 1,25-dihydroxy vitamin D concentration, and Ca absorption/reabsorption, thus contributing to the positive effects of GH on bone. On the other hand, in post-menopausal women with primary hyperparathyroidism a reduced secretion of GH is observed, in association with a greater impairment of bone mass. GH administration resulted in increased IGF-I concentration, decreased PTH concentration, and increased nephrogenous cAMP. In conclusion, the anabolic action of PTH requires paracrine and autocrine effects of IGF-I.",
author = "G. Lombardi and {Di Somma}, C. and L. Vuolo and E. Guerra and E. Scarano and A. Colao",
year = "2010",
language = "English",
volume = "33",
pages = "22--26",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "7 Suppl",

}

TY - JOUR

T1 - Role of IGF-I on PTH effects on bone.

AU - Lombardi, G.

AU - Di Somma, C.

AU - Vuolo, L.

AU - Guerra, E.

AU - Scarano, E.

AU - Colao, A.

PY - 2010

Y1 - 2010

N2 - IGF-I and PTH have synergistic actions on bone and some effects of the anabolic actions of PTH are mediated by local production of IGF-I, as has been shown in vitro and in vivo studies both in animals and humans. PTH can induce skeletal IGF-I expression both in vitro and in vivo. In chondrocytes, IGF-I synthesis is under GH control, whereas in osteoblasts its synthesis is fundamentally under the control of PTH. PTH stimulates the synthesis of IGF-I via a cAMP-dependent mechanism, and this factor has pro-differentiating and prosurvival effects on osteoblasts. In in vitro studies, IGF-I and PTH have shown a synergistic action on the osteoblasts of bone marrow. Human clinical data confirm the interactions between PTH and GH-IGF-I axis on bone. PTH is involved in the development of osteoporosis in adult patients with GH deficiency (GHD). In fact, patients with GHD show renal, skeletal, and intestinal cell insensitivity to PTH, leading to a mild state of PTH resistance and increased serum PTH levels. In addition, GH replacement in these patients restores PTH secretory rhythm, increases bone turnover markers, 1,25-dihydroxy vitamin D concentration, and Ca absorption/reabsorption, thus contributing to the positive effects of GH on bone. On the other hand, in post-menopausal women with primary hyperparathyroidism a reduced secretion of GH is observed, in association with a greater impairment of bone mass. GH administration resulted in increased IGF-I concentration, decreased PTH concentration, and increased nephrogenous cAMP. In conclusion, the anabolic action of PTH requires paracrine and autocrine effects of IGF-I.

AB - IGF-I and PTH have synergistic actions on bone and some effects of the anabolic actions of PTH are mediated by local production of IGF-I, as has been shown in vitro and in vivo studies both in animals and humans. PTH can induce skeletal IGF-I expression both in vitro and in vivo. In chondrocytes, IGF-I synthesis is under GH control, whereas in osteoblasts its synthesis is fundamentally under the control of PTH. PTH stimulates the synthesis of IGF-I via a cAMP-dependent mechanism, and this factor has pro-differentiating and prosurvival effects on osteoblasts. In in vitro studies, IGF-I and PTH have shown a synergistic action on the osteoblasts of bone marrow. Human clinical data confirm the interactions between PTH and GH-IGF-I axis on bone. PTH is involved in the development of osteoporosis in adult patients with GH deficiency (GHD). In fact, patients with GHD show renal, skeletal, and intestinal cell insensitivity to PTH, leading to a mild state of PTH resistance and increased serum PTH levels. In addition, GH replacement in these patients restores PTH secretory rhythm, increases bone turnover markers, 1,25-dihydroxy vitamin D concentration, and Ca absorption/reabsorption, thus contributing to the positive effects of GH on bone. On the other hand, in post-menopausal women with primary hyperparathyroidism a reduced secretion of GH is observed, in association with a greater impairment of bone mass. GH administration resulted in increased IGF-I concentration, decreased PTH concentration, and increased nephrogenous cAMP. In conclusion, the anabolic action of PTH requires paracrine and autocrine effects of IGF-I.

UR - http://www.scopus.com/inward/record.url?scp=79952110332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952110332&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 22

EP - 26

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 7 Suppl

ER -